WO1999010004A3 - Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto - Google Patents

Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto Download PDF

Info

Publication number
WO1999010004A3
WO1999010004A3 PCT/US1998/017922 US9817922W WO9910004A3 WO 1999010004 A3 WO1999010004 A3 WO 1999010004A3 US 9817922 W US9817922 W US 9817922W WO 9910004 A3 WO9910004 A3 WO 9910004A3
Authority
WO
WIPO (PCT)
Prior art keywords
hedgehog
polypeptides
formulations
regulation
therapeutic
Prior art date
Application number
PCT/US1998/017922
Other languages
French (fr)
Other versions
WO1999010004A2 (en
Inventor
Chris S Bladgen
Peter D Currie
Philip W Ingham
Simon M Hughes
Original Assignee
Ontogeny Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ontogeny Inc filed Critical Ontogeny Inc
Priority to AU91252/98A priority Critical patent/AU9125298A/en
Priority to EP98943462A priority patent/EP1009424A2/en
Priority to CA002302780A priority patent/CA2302780A1/en
Publication of WO1999010004A2 publication Critical patent/WO1999010004A2/en
Publication of WO1999010004A3 publication Critical patent/WO1999010004A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Abstract

The present application relates to a method for modulating the formation and/or maintenance of muscle tissue by ectopically contacting muscle cells, especially muscle stem/progenitor cells, in vitro or in vivo, with a hedgehog therapeutic or ptc therapeutic in an amount effective to alter the growth state the treated cells, e.g., relative to the absence of administration of the hedgehog therapeutic or ptc therapeutic.
PCT/US1998/017922 1997-08-29 1998-08-28 Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto WO1999010004A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU91252/98A AU9125298A (en) 1997-08-29 1998-08-28 Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto
EP98943462A EP1009424A2 (en) 1997-08-29 1998-08-28 Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto
CA002302780A CA2302780A1 (en) 1997-08-29 1998-08-28 Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5739497P 1997-08-29 1997-08-29
US60/057,394 1997-08-29

Publications (2)

Publication Number Publication Date
WO1999010004A2 WO1999010004A2 (en) 1999-03-04
WO1999010004A3 true WO1999010004A3 (en) 1999-05-27

Family

ID=22010324

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/017922 WO1999010004A2 (en) 1997-08-29 1998-08-28 Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto

Country Status (4)

Country Link
EP (1) EP1009424A2 (en)
AU (1) AU9125298A (en)
CA (1) CA2302780A1 (en)
WO (1) WO1999010004A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8173098A (en) 1997-06-27 1999-01-19 Ontogeny, Inc. Neuroprotective methods and reagents
US7144997B2 (en) 1997-07-24 2006-12-05 Curis, Inc. Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6639051B2 (en) 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
US6884770B1 (en) 1998-11-06 2005-04-26 Curis, Inc. Methods and compositions for treating or preventing peripheral neuropathies
US20030083242A1 (en) * 1998-11-06 2003-05-01 Alphonse Galdes Methods and compositions for treating or preventing peripheral neuropathies
WO2000041537A2 (en) * 1999-01-14 2000-07-20 Eli Lilly And Company Use of desert hedgehog protein
IL146842A0 (en) * 1999-06-01 2002-07-25 Biogen Inc Polymer conjugates of hedgehog proteins and uses
US20070021493A1 (en) 1999-09-16 2007-01-25 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
CA2385736C (en) * 1999-09-16 2011-11-15 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US8852937B2 (en) 2000-03-30 2014-10-07 Curis, Inc. Small organic molecule regulators of cell proliferation
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
US6683192B2 (en) * 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
US6683108B1 (en) * 2000-03-30 2004-01-27 Curis, Inc. Agonists of hedgehog signaling pathways and uses related thereto
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
US7708998B2 (en) 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
CA2425356C (en) 2000-10-13 2015-10-06 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
DK1730280T3 (en) 2004-03-26 2019-02-04 Curis Inc RNA interference modulators for hedgehog signaling and applications thereof
AU2009209702A1 (en) * 2008-01-29 2009-08-06 Novartis Ag Use of Hedgehog agonists in the treatment of musculoskeletal-related disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3942114A1 (en) * 1988-12-26 1990-06-28 Hiroyoshi Hidaka New isoquinoline:sulphonamide and naphthalene:sulphonamide cpds.
WO1995018856A1 (en) * 1993-12-30 1995-07-13 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing hedgehog-like proteins
WO1996017924A2 (en) * 1994-12-02 1996-06-13 The Johns Hopkins University School Of Medicine Novel hedgehog-derived polypeptides
WO1997004761A1 (en) * 1995-07-28 1997-02-13 Trustees Of Boston University Methods and compositions for treating cell proliferative disorders
WO1998048830A1 (en) * 1997-04-28 1998-11-05 Trustees Of The University Of Pennsylvania Method for promoting myogenesis using osteogenic proteins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3942114A1 (en) * 1988-12-26 1990-06-28 Hiroyoshi Hidaka New isoquinoline:sulphonamide and naphthalene:sulphonamide cpds.
WO1995018856A1 (en) * 1993-12-30 1995-07-13 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing hedgehog-like proteins
WO1996017924A2 (en) * 1994-12-02 1996-06-13 The Johns Hopkins University School Of Medicine Novel hedgehog-derived polypeptides
WO1997004761A1 (en) * 1995-07-28 1997-02-13 Trustees Of Boston University Methods and compositions for treating cell proliferative disorders
WO1998048830A1 (en) * 1997-04-28 1998-11-05 Trustees Of The University Of Pennsylvania Method for promoting myogenesis using osteogenic proteins

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
A.E. MÜNSTERBERG ET AL.: "COMBINATORIAL SIGNALING BY SONIC HEDGEHOG AND Wnt FAMILY MEMBERS INDUCES MYOGENIC bHLH GENE EXPRESSION IN THE SOMITE", GENES AND DEVELOPMENT, vol. 9, no. 23, 1995, pages 2911 - 2922, XP002098540 *
C.S. BLAGDEN ET AL.: "NOTOCHORD INDUCTION OF ZEBRAFISH SLOW MUSCLE MEDIATED BY SONIC HEDGEHOG", GENES AND DEVELOPMENT, vol. 11, no. 17, 1 September 1997 (1997-09-01), pages 2163 - 2175, XP002098537 *
D. DUPREZ ET AL.: "SONIC HEDGEHOG INDUCES PROLIFERATION OF COMMITTED SKELETAL MUSCLE CELLS IN THE CHICK LIMB", DEVELOPMENT, vol. 125, no. 3, February 1998 (1998-02-01), pages 495 - 505, XP002098538 *
E.J. AW ET AL.: "MYOGENESIS IN VITRO. ENHANCEMENT BY DIBUTYRYL cAMP", EXPERIMENTAL CELL RESEARCH, vol. 83, no. 2, 1974, pages 436 - 438, XP002098543 *
HAMMERSCHMIDT M ET AL: "Protein kinase A is a common negative regulator of Hedgehog signaling in the vertebrate embryo", GENES AND DEVELOPMENT, vol. 10, no. 6, 15 March 1996 (1996-03-15), pages 647 - 658, XP002092607 *
K. STYGALL ET AL.: "THE EFFECT OF CHOLERA TOXIN ON MYOGENESIS IN RAT SKELETAL MUSCLE CULTURES", DEVELOPMENTAL BIOLOGY, vol. 78, no. 1, 1980, pages 14 - 24, XP002098544 *
L.M. WASSERMAN ET AL.: "cAMP EFFECTS ON MYOGENIC GENE EXPRESSION IN RHABDOMYOSARCOMA CELLS", EXPERIMENTAL CELL RESEARCH, vol. 227, no. 1, 1996, pages 55 - 62, XP002098539 *
P.D. CURRIE ET AL.: "INDUCTION OF A SPECIFIC MUSCLE CELL TYPE BY A HEDGEHOG-LIKE PROTEIN IN ZEBRAFISH", NATURE, vol. 382, no. 6590, 1996, pages 452 - 455, XP002098542 *
S.H. DEVOTO ET AL.: "ZEBRAFISH MUSCLE FIBER TYPE DEVELOPMENT IS REGULATED BY COMPETING INFLUENCES OF HEDGEHOG AND TGF-beta GENE FAMILY MEMBERS", DEVELOPEMNT BIOLOGY, vol. 186, no. 2, June 1997 (1997-06-01), pages 321, XP002098541 *

Also Published As

Publication number Publication date
AU9125298A (en) 1999-03-16
WO1999010004A2 (en) 1999-03-04
EP1009424A2 (en) 2000-06-21
CA2302780A1 (en) 1999-03-04

Similar Documents

Publication Publication Date Title
WO1999010004A3 (en) Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto
WO2001064238A3 (en) Methods and compositions for regulating adipocytes
EP0845268A3 (en) Composition for treating cornea
IL111734A0 (en) Compositions for the preparation of in vivo therapeutic products
PL326064A1 (en) Growth factor containing gel forms
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
WO1997034586A3 (en) Device and method for treating ophthalmic diseases
AU2369595A (en) In vitro growth of functional islets of langerhans and in vivo uses thereof
DK1061940T3 (en) Use of follistatin for the manufacture of a medicament for the treatment of muscle related disorders
IL121790A0 (en) Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor (GDNF) protein product
EP0923293A4 (en) Treatment of diarrhea
HUP9802665A3 (en) Composition for controlled release of miotic and mydriatic drugs in the anterior chamber
CA2293575A1 (en) Controlled release microencapsulated ngf formulation
AU6331898A (en) Forskohlin for promoting lean body mass
WO2002038171A3 (en) METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE
CA2295199A1 (en) Method for treating vascular proliferative diseases with p27 and fusions thereof
WO2000015246A3 (en) Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto
WO2002007749A3 (en) Device providing regulated growth factor delivery for the regeneration of peripheral nerves
WO2000034442A3 (en) Application of shear flow stress to smooth muscle cells for the production of implantable structures
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
CA2222698A1 (en) Use of bradykinin antagonists for stimulating or inducing hair growth and/or arresting hair loss
DE69632967D1 (en) PREVENTION OF GRASS REPELLATION IN TRANSPLANTS AND FOR THE PRODUCTION OF UNIVERSAL GENE THERAPY IN THE CELL, USING LYMPHOYCYTE ACTIVATION GENE-3 (LAG-3)
ITRM970238A0 (en) USE OF THE NERVE GROWTH FACTOR IN THE PRESERVATION OF CORNEAS IN CULTURE, IN THE PRODUCTION OF CORNEAL AND CONJUNCTIVAL TISSUES IN VITRO AND IN THE THERAPY OF CORNEAL AND CONJUNCTIVAL DISEASES
CA2073453A1 (en) Methods of enhancing wound healing and tissue repair
AU5026600A (en) Methods of regulating the condition of mammalian keratinous tissue

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2302780

Country of ref document: CA

Ref country code: CA

Ref document number: 2302780

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 91252/98

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998943462

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998943462

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998943462

Country of ref document: EP